» Articles » PMID: 12839963

Correlating Genetic Aberrations with World Health Organization-defined Histology and Stage Across the Spectrum of Thymomas

Overview
Journal Cancer Res
Specialty Oncology
Date 2003 Jul 4
PMID 12839963
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Thymomas are thymic epithelial tumors. Because most of them are rich in nonneoplastic T-cells, recurrent genetic aberrations have been reported only in the rare, lymphocyte-poor WHO types A, B3, and C. We have now investigated virtually the whole spectrum of thymomas, including the commoner types AB and B2, microdissecting or culturing neoplastic cells from these lymphocyte-rich thymomas and applying 41 microsatellite markers covering 17 loci on 10 chromosomes. In 28 cases, comparative genomic hybridization data were available. Apart from type A, there was striking heterogeneity between thymomas. Allelic imbalances were seen in 87.3% of the 55 cases, and MSI in 9.9%. Losses of heterozygosity (LOHs) were much the commonest aberration. Overall, they were most prevalent at four regions on chromosome 6. Aberrations elsewhere, affecting mainly 8p11.21 and 7p15.3, suggested a cortical footprint because they recurred only in the thymopoietically active type AB and B thymomas. LOHs were also seen at the adenomatous polyposis coli (APC) locus (5q21-22) in subsets of these thymomas, whereas combined LOHs at the APC, retinoblastoma (13q14.3), and p53 (17p13.1) loci were confined to a subset of B3 thymomas that had possibly evolved from APC-hemizygous B2 thymomas by tumor progression; indeed, thymomas combing B2 plus B3 features are common. Notably, some AB and B thymomas shared LOHs despite their nonoverlapping morphology and different clinical behavior. Finally, allelic imbalances at 8p11.21 and 16q22.1 (CDH1) were significantly more frequent in stage IV metastatic thymomas. We conclude that the WHO-defined histological thymoma types generally segregate with characteristic genetic features, type A thymomas being the most homogeneous. Many findings support the view that B2 and B3 thymomas form a continuum, with evidence of tumor progression. However, other findings imply that types A and AB are biologically distinct from the others, any potential invasiveness being severely restricted by a medullary commitment in the precursor cell undergoing neoplastic transformation.

Citing Articles

DNA-Methylation Analysis as a Tool for Thymoma Classification.

Gaiser T, Hirsch D, Porth I, Sahm F, Strobel P, von Deimling A Cancers (Basel). 2022; 14(23).

PMID: 36497358 PMC: 9738683. DOI: 10.3390/cancers14235876.


Molecular pathology of thymomas: implications for diagnosis and therapy.

Marx A, Belharazem D, Lee D, Popovic Z, Reissfelder C, Schalke B Virchows Arch. 2021; 478(1):101-110.

PMID: 33674910 PMC: 7966134. DOI: 10.1007/s00428-021-03068-8.


Expression of molecules of the Wnt pathway and of E-cadherin in the etiopathogenesis of human thymomas.

Vodicka P, Krskova L, Odintsov I, Krizova L, Sedlackova E, Schutzner J Oncol Lett. 2020; 19(3):2413-2421.

PMID: 32194741 PMC: 7039126. DOI: 10.3892/ol.2020.11343.


Immune biomarkers in thymic epithelial tumors: expression patterns, prognostic value and comparison of diagnostic tests for PD-L1.

Rouquette I, Taranchon-Clermont E, Gilhodes J, Bluthgen M, Perallon R, Chalabreysse L Biomark Res. 2019; 7:28.

PMID: 31827799 PMC: 6894111. DOI: 10.1186/s40364-019-0177-8.


Genomic Analysis of Thymic Epithelial Tumors Identifies Novel Subtypes Associated with Distinct Clinical Features.

Lee H, Jang H, Shah R, Yoon D, Hamaji M, Wald O Clin Cancer Res. 2017; 23(16):4855-4864.

PMID: 28400429 PMC: 5559309. DOI: 10.1158/1078-0432.CCR-17-0066.